Patents by Inventor Perrine Martin
Perrine Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230256057Abstract: The present invention is in the field of immunotherapy. The invention provides non-propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.Type: ApplicationFiled: July 13, 2021Publication date: August 17, 2023Applicant: TransgeneInventors: Geneviève INCHAUSPE, Perrine MARTIN, Stéphane LEUNG-THEUNG-LONG, Karine LELU-SANTOLARIA, Alexei EVLACHEV, Charles Antoine COUPET, Aurélie RAY, Clarisse DUBOIS
-
Patent number: 10857226Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: September 17, 2018Date of Patent: December 8, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Patent number: 10662414Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: January 25, 2019Date of Patent: May 26, 2020Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20190328869Abstract: The present invention provides an immunotherapeutic composition for use in combination with one or more MDSC (Myeloid-derived suppressor cells) modulator(s) and a kit of parts comprising such components as well as methods using such components in combination. The invention also provides the use of Phosphodiesterase-5 (PDE5) inhibitors for reversing immunosuppression in chronic infectious diseases. The invention is of very special interest in treating or preventing diseases, especially chronic infectious diseases such as hepatitis B.Type: ApplicationFiled: October 10, 2017Publication date: October 31, 2019Applicant: Transgene SAInventors: Karine Lelu-Santolaria, Roland Kratzer, Perrine Martin
-
Publication number: 20190144840Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: January 25, 2019Publication date: May 16, 2019Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20190070285Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: September 17, 2018Publication date: March 7, 2019Applicant: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Patent number: 10190105Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: December 5, 2016Date of Patent: January 29, 2019Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 10076570Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: March 17, 2012Date of Patent: September 18, 2018Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Publication number: 20170145392Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: December 5, 2016Publication date: May 25, 2017Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20170072047Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: July 6, 2016Publication date: March 16, 2017Applicant: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Patent number: 9512412Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: GrantFiled: July 12, 2012Date of Patent: December 6, 2016Assignee: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 9393299Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: GrantFiled: August 6, 2010Date of Patent: July 19, 2016Assignee: Transgene S.A.Inventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Publication number: 20140287480Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: July 12, 2012Publication date: September 25, 2014Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Publication number: 20130011435Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: August 6, 2010Publication date: January 10, 2013Applicant: Transgene SAInventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Patent number: 8293528Abstract: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.Type: GrantFiled: December 17, 2009Date of Patent: October 23, 2012Assignees: Transgene SA, INSERM (Institut National de la Sante et de la Reserche Medicale)Inventors: Geneviève Inchauspe, Anne Fournillier, Nourredine Himoudi, Perrine Martin
-
Publication number: 20120251569Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: March 17, 2012Publication date: October 4, 2012Applicant: TRANSGENE SAInventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Publication number: 20110020398Abstract: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.Type: ApplicationFiled: December 17, 2009Publication date: January 27, 2011Inventors: Geneviève Inchauspe, Anne Fournillier, Nourredine Himoudi, Perrine Martin
-
Publication number: 20070072176Abstract: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.Type: ApplicationFiled: August 11, 2006Publication date: March 29, 2007Inventors: Genevieve Inchauspe, Anne Fournillier, Nourredine Himoudi, Perrine Martin